• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway.
Authors: Li J, Liu W, Hao H, Wang Q, Xue L Abstract Chronic myelogenous leukemia (CML) is a common hematological malignancy. Some patients progressing to the blast phase develop chemotherapeutic drug resistance. In the authors' previous study, it was found that the mammalian target of rapamycin (mTOR) pathway was activated in CML and that rapamycin inhibited the proliferation of K562 cells. Targeting the mTOR pathway may be used in combination with chemotherapeutic drugs to enhance their efficacy and overcome multidrug resistance. The aim of the present study was to investigate the effects of rapamycin and doxorubi...
Source: Oncology Letters - August 14, 2019 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells.
Authors: Yang JZ, Huang LH, Chen R, Meng LJ, Gao YY, Ji QY, Wang Y Abstract Multidrug resistance (MDR) is a major challenge for the management of the majority of cancers. The precise molecular mechanisms of MDR remain elusive. In a previous study, a multidrug resistant osteosarcoma model [MG63/vincristine (VCR)] was established by intermittent exposure of MG63 cells to gradually increasing concentrations of VCR. These cells exhibited cross-resistance to multiple structurally and mechanistically unrelated chemotherapeutic agents. The development of MDR was associated with increased expression of LIM kinase 1 (LIMK1)...
Source: Oncology Letters - February 3, 2018 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells.
Authors: Xia ZS, Wu D, Zhong W, Lu XJ, Yu T, Chen QK Abstract Colon cancer is one of the most common cancers in the world. Multidrug resistance is one of the main reasons for failure of therapy in patients with advanced colon cancer. In previous studies, multiple methods were investigated to reverse the multidrug resistance of colon cancer cells. However, to date, no clinical method has been identified to be satisfactory. Therefore, successful reversal of drug resistance in colon cancer cells still requires new therapeutic strategies or pharmaceuticals. Wild-type p53-induced phosphatase (Wip1), a member of the 2C t...
Source: Oncology Letters - August 9, 2017 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research